Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma - sprookjes - yvandenbroek - TriplyDB

Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma

Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma

http://www.wikidata.org/entity/Q56461562

about

Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549)Molecularly defined antibody conjugation through a selenocysteine interface.Possible role of CD22, CD79b and CD20 expression in distinguishing small lymphocytic lymphoma from chronic lymphocytic leukemia.Time-to-Event Analysis of Polatuzumab Vedotin-Induced Peripheral Neuropathy to Assist in the Comparison of Clinical Dosing Regimens.Improving the serum stability of site-specific antibody conjugates with sulfone linkers.Ofatumumab, a human anti-CD20 monoclonal antibody.Strategies and challenges for the next generation of therapeutic antibodies.A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.Reorienting the Fab domains of trastuzumab results in potent HER2 activators.Synthesis of a covalent epirubicin-(C(3)-amide)-anti-HER2/neu immunochemotherapeutic utilizing a UV-photoactivated anthracycline intermediate Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate.Hetero-modification of TRAIL trimer for improved drug delivery and in vivo antitumor activities.Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo.Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer.Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells.Targeted treatment and new agents in diffuse large B cell lymphoma.Investigational antibody-drug conjugates for hematological malignancies.Pharmacokinetic considerations for antibody drug conjugates.Optimising the delivery of tubulin targeting agents through antibody conjugation.Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia.Stable and Potent Selenomab-Drug Conjugates.Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma.Featured Article: Delivery of chemotherapeutic vcMMAE using tobacco mosaic virus nanoparticles.Integrative computational analysis of transcriptional and epigenetic alterations implicates DTX1 as a putative tumor suppressor gene in HNSCC The HB22.7-vcMMAE antibody-drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity.Antibody Drug Conjugates (ADCs): Changing the Treatment Landscape of Lymphoma.DropArray™, a wall-less 96-well plate for uptake and immunofluorescence microscopy, confirms CD22 recycles.Semi-mechanistic Multiple-Analyte Pharmacokinetic Model for an Antibody-Drug-Conjugate in Cynomolgus Monkeys.An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: case study of TENB2.CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma.The collagen receptor uPARAP/Endo180 as a novel target for antibody-drug conjugate mediated treatment of mesenchymal and leukemic cancers.Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates.Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma.Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs).Rehabilitation or the death penalty: autoimmune B cells in the dock.

P2860

Q26780335-0B0D6DC9-DAC6-46C9-A030-CDC8ABBB8308 Q28829762-AE4DDA99-990F-492D-BC66-536CC2F5FC69 Q33675575-D02269F9-0F0F-4468-BE0D-93481C1ED133 Q33683659-DEF39C4C-F28F-46BC-8D73-D4841727CF1D Q33845533-BA1B626A-EEB8-4479-BACE-B9846BF63291 Q34074771-3B6DD5DA-4F16-4C43-B51A-B5CC07614F3B Q34095311-1E7637C7-28D5-4A83-8C0B-7D7A95584D12 Q34111699-E2556A8F-469E-4511-87BD-CB22D66DA12C Q34302726-F299E63E-DDE4-426E-BA9C-7AB32C3C5C8C Q34532338-FEF91B5A-8FB0-4800-BDC7-14BDD8AABC4C Q35180943-0619AF12-69F4-4886-9CA9-504808B4CE1B Q35946005-E71F0990-788B-4779-B765-01A604772A66 Q36134152-A7443094-0B14-43A0-A13B-C34547031A3D Q36619787-F2500349-B194-4F88-A8C6-77B05676A786 Q36824455-8FD3BAAA-C346-45A1-BC54-88699F00D9AB Q37013285-CC3A7983-9279-4DEA-9BFE-A54D9F54BA0C Q37723164-95546848-EF5F-4FC7-8965-BA2118239A66 Q37766121-EE63F2A4-26D0-455B-9FC7-E9664F51B8CA Q37818256-CEE1FF33-A4C4-4856-8AF2-B72387EA7EAC Q38022192-8770A814-F253-4A3A-8549-BC222D997C13 Q38024991-5BB1CFCF-8296-4AC3-9D30-E9C5A461245F Q38087390-54C179CC-8B46-4BB7-A638-67E5AEAA351C Q38432502-2C03F844-1967-416B-A34E-E186C0482233 Q38550992-926C7B66-E03E-42C7-9BBA-7A4BC0E0F2AF Q38694867-4A37E75B-91EB-470D-AADE-F2DD35868730 Q38718489-E3E0548D-BE31-4784-A6F5-750E42675BB4 Q38752841-B7928C4B-5C6F-49D5-A01D-B784781B18D1 Q38932868-D15CDE6E-9F3D-49BA-9E06-771AFBFEBEF1 Q39044402-773F1596-6485-46D8-8EA6-69CE8BE2ADDA Q39085203-E21EC471-852D-40F4-85FF-2706E863CD75 Q39298392-39833337-D588-4B5D-8685-7725A117E1DC Q39575135-059EDC88-9DC9-4257-87D1-0A18C6E225ED Q41280225-9B6AC730-8A4C-4B81-AB4E-A4849CE156D2 Q41282870-7CB28596-1CE9-408C-8152-55BB219D63FD Q42558833-AD06D068-5C68-4D7F-8B3B-5A539307F496 Q42646020-99893C3F-8466-4278-9815-718E6CFD8562 Q42993852-7F3C8093-092F-4528-8B56-93D730A9AD1A Q48222343-479A39FF-EC34-4BC0-90A8-B8AB1481E254 Q52704026-840C25A1-67FB-47C4-83F4-D2B505963477 Q53630006-479782A6-12B8-4578-A9E8-E3291AF2ECE4

P2860

Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma

http://www.wikidata.org/entity/Q56461562

description

article

@en

im Juli 2009 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в липні 2009

@uk

ലേഖനം

@ml

name

Therapeutic potential of an an ...... atment of non-Hodgkin lymphoma

@en

Therapeutic potential of an an ...... atment of non-Hodgkin lymphoma

@en-gb

Therapeutic potential of an an ...... atment of non-Hodgkin lymphoma

@nl

type

label

Therapeutic potential of an an ...... atment of non-Hodgkin lymphoma

@en

Therapeutic potential of an an ...... atment of non-Hodgkin lymphoma

@en-gb

Therapeutic potential of an an ...... atment of non-Hodgkin lymphoma

@nl

prefLabel

Therapeutic potential of an an ...... atment of non-Hodgkin lymphoma

@en

Therapeutic potential of an an ...... atment of non-Hodgkin lymphoma

@en-gb

Therapeutic potential of an an ...... atment of non-Hodgkin lymphoma

@nl

P1433

Q56461562-A377AD0D-7C11-49C2-8487-51D7320045BB

P1476

Q56461562-F5EE6BF3-2AD3-40DD-9005-F19D41F6468C

P2093

Q56461562-12ED02DE-8D7F-4C4E-81D9-1C27D7CCF58C

Q56461562-17DB5100-12B2-4E1E-BD72-B59E2BD9B545

Q56461562-23A91E0E-4975-449C-ADC3-B41F1FA2A53F

Q56461562-2BBFC7BC-EF19-4EC8-936B-C62D1568F733

Q56461562-371512D0-FA7E-4E3D-A761-1498B038D404

Q56461562-3C0A3CD6-6891-4FBD-BDAE-C41B5E7CD409

Q56461562-479E6411-E265-44FC-ABC7-DA5B75596032

Q56461562-4FBD1155-08B3-4A7C-B910-14833F563F91

Q56461562-58736E6A-C6ED-46D4-B7BF-C7162C1BBE3D

Q56461562-65AC7225-9EC5-45AE-B785-20CCC001E585

P304

Q56461562-03CBB43D-646B-4CA6-AC0F-299465960FBA

P31

Q56461562-2D3490B5-4B9E-458A-91C6-104F03BBB043

P356

Q56461562-97906B19-8A95-47D6-940E-3BD79756046F

P407

Q56461562-3CB46E36-C70F-470E-909D-889221E41191

P433

Q56461562-696D3BC0-A8D8-4532-8D75-4C1C8116EF9C

P478

Q56461562-7E642CE0-1DF4-4535-AD31-0C3DE152FD2B

P50

Q56461562-040A5925-5629-448C-94B8-8A32BDA4A765

Q56461562-138614C2-759F-4F93-8B7D-DA89DC1DED84

P577

Q56461562-89014497-04E6-4151-8E7A-B05D6F0EA665

P698

Q56461562-C701A927-53DE-4348-BD05-106220EB6139

P921

Q56461562-166B8896-D797-4585-AAE6-647FAC12019A

P356

BLOOD-2009-02-205500

P1433

P1476

Therapeutic potential of an an ...... atment of non-Hodgkin lymphoma

@en

P2093

Allen Ebens

http://www.w3.org/2001/XMLSchema#string

Andrew G Polson

http://www.w3.org/2001/XMLSchema#string

Andrew Jack

http://www.w3.org/2001/XMLSchema#string

Bing Zheng

http://www.w3.org/2001/XMLSchema#string

Dan Eaton

http://www.w3.org/2001/XMLSchema#string

David Dornan

http://www.w3.org/2001/XMLSchema#string

Dorothy French

http://www.w3.org/2001/XMLSchema#string

Fiona Bennett

http://www.w3.org/2001/XMLSchema#string

Hartmut Koeppen

http://www.w3.org/2001/XMLSchema#string

Jacqueline McBride

http://www.w3.org/2001/XMLSchema#string

P304

2721-2729

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2009-02-205500

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

114

http://www.w3.org/2001/XMLSchema#string

P50

Andy C Rawstron

Jagath R Junutula

P577

2009-07-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19633198

http://www.w3.org/2001/XMLSchema#string

P921